Since QMSP does not provide methylation frequency at individual CpG sites, we suggest pyrosequencing as the best approach to investigate the pattern of CpGs methylation in the promoter region of KEAP1. The validation of this approach on lung cancer patient cohorts is essential to clarify the prognostic value of the epigenetic deregulation of KEAP1 in lung tumors. This evidence concerns the gene KEAP1 and lung carcinoma.